Response to peginterferon-alpha 2b and ribavirin in Japanese patients with chronic hepatitis C genotype 1 |
| |
Authors: | Tomoo Miyauchi Tatsuo Kanda Fumio Imazeki Rintaro Mikata Akinobu Tawada Makoto Arai Keiichi Fujiwara Shingo Nakamoto Shuang Wu Takeshi Tanaka Tatsuo Miyamura Michio Kimura Yasuo Hirai Motohide Takashi Shigeru Mikami Nobuyuki Sugiura Yutaka Natsuki Ryosaku Azemoto Noriaki Suzuki Osamu Yokosuka |
| |
Institution: | 1. Department of Medicine and Clinical Oncology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8670, Japan 2. Social Insurance Funabashi Chuo Hospital, Funabashi, 273-8566, Japan 3. Matsudo City Hospital, Matsudo, 271-8511, Japan 4. Saiseikai Narashino Hospital, Narashino, 275-0006, Japan 5. Kikkoman Hospital, Noda, 278-0005, Japan 6. National Hospital Organization Chiba Medical Center, Chiba, 263-0042, Japan 7. Sannou Hospital Medical Center, Chiba, 263-0002, Japan 8. Kimitsu Chuo Hospital, Kisarazu, 292-8535, Japan
|
| |
Abstract: | Purpose Patient age and gender may be associated with response to peginterferon alpha plus ribavirin, the current standard of care (SOC) for chronic hepatitis C genotype 1. We queried whether there was an association between age, gender, and treatment response to SOC in Japanese patients infected with hepatitis C virus (HCV) genotype 1. Methods Between 2006 and 2009, HCV-infected Japanese patients treated with peginterferon alpha-2b plus ribavirin for 48 weeks were enrolled. Patients were allocated into four groups according to age and gender, and epidemiological data and treatment outcomes were retrospectively analyzed. HCV RNA was measured with COBAS AMPLICOR HCV Monitor Test v. 2.0. Results The overall sustained virological response (SVR) rate was 49.8%: patients aged ≤65 and >65 years, 50.9 and 44.0%, respectively; male and female, 56.5 and 39.0%. SVR rates of SOC against HCV genotype-1 females aged >65 years (19.0%) were inferior to those in males aged >65 years (57.8%) in Japan. Multivariate logistic regression analysis showed that SVR was attained independently of adherence 80/80/80 in all groups. Conclusions Adherence to medication is also a key factor for the eradication of HCV in patients aged >65 years. As the SVR rate of patients aged ≤65 years was similar to that of patients aged >65 years, SOC could be useful for treating some of the elderly patients. |
| |
Keywords: | |
本文献已被 SpringerLink 等数据库收录! |
|